Herui Yao
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer (NCT04263298) | Herui Yao | 2018-05-01 |
Track Herui Yao automatically
Every clearance here is in the API, with alerts when new ones post.